| 1 |
Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation： report of a nationwide French registry and the development of a new prognostic score[J]. J Clin Oncol, 2013, 31(10)：1302-1309.
|
| 2 |
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6)：549-562.
|
| 3 |
Sampaio MS, Cho YW, Shah T, et al. Impact of epstein-barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients[J].Nephrol Dial Transplant, 2012, 27(7)：2971-2979.
|
| 4 |
Augustine J. Kidney transplant： new opportunities and challenges[J]. Cleve Clin J Med, 2018, 85(2)：138-144.
|
| 5 |
Styczynski J, Gil L, Tridello G, et al； Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.Response to rituximab-based therapy and risk factor analysis in epstein barrvirus-relatedlymphoproliferativedisorderafter hematopoietic stem cell transplant in children and adults： a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation[J]. Clin Infect Dis, 2013, 57(6)：794-802.
|
| 6 |
Chua A, Cramer C, Moudgil A, et al； NAPRTCS investigators.Kidney transplant practice patterns and outcome benchmarks over 30 years： the 2018 report of the NAPRTCS[J]. Pediatr Transplant,2019, 23(8)：e13597.
|
| 7 |
Al-Mansour Z,NelsonBP,EvensAM.Post-transplant lymphoproliferative disease (PTLD)： risk factors, diagnosis, and current treatment strategies[J]. Curr Hematol Malig Rep, 2013, 8(3)：173-183.
|
| 8 |
Atallah-Yunes SA, Salman O, Robertson MJ. Post-transplant lymphoproliferative disorder： update on treatment and novel therapies[J]. Br J Haematol, 2023, 201(3)：383-395.
|
| 9 |
Le J, Durand CM, Agha I, et al. Epstein-barr virus and renal transplantation[J]. Transplant Rev (Orlando), 2017, 31(1)：55-60.
|
| 10 |
Cazzola M. Introduction to a review series： the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues[J]. Blood, 2016, 127(20)：2361-2364.
|
| 11 |
刘启发, 林韧. 造血干细胞移植后EB病毒相关PTLD的诊疗进展[J]. 临床血液学杂志, 2019, 32(9)：656-659.
|
| 12 |
林芳, 沈茜, 徐虹, 等. 儿童肾移植术后淋巴组织增生性疾病两例报告暨文献复习[J]. 中华肾脏病杂志, 2021, 37(3)：8.
|
| 13 |
Krams SM, Martinez OM. Epstein-barr virus, rapamycin, and host immune responses[J]. Curr Opin Organ Transplant, 2008, 13(6)：563-568.
|
| 14 |
Nourse JP, Jones K, Gandhi MK. Epstein-barr virus-related posttransplant lymphoproliferative disorders： pathogenetic insights for targeted therapy[J]. Am J Transplant, 2011, 11(5)：888-895.
|
| 15 |
Dharnidharka VR, Webster AC, Martinez OM, et al. Post-transplant lymphoproliferative disorders[J]. Nat Rev Dis Primers, 2016, 2：15088.
|
| 16 |
Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder： analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8)：1076-1088.
|
| 17 |
Mynarek M, Hussein K, Kreipe HH, et al. Malignancies after pediatric kidney transplantation： more than PTLD?[J]. Pediatr Nephrol, 2014, 29(9)：1517-1528.
|
| 18 |
施丹, 高志刚. 儿童肝移植术后淋巴增殖性疾病研究进展[J/CD].中华移植杂志：电子版, 2022, 16(3)： 174-178.
|
| 19 |
Francis A, Johnson DW, Teixeira-Pinto A, et al. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood： a registry study[J].Nephrol Dial Transplant, 2018, 33(5)：881-889.
|
| 20 |
Fulchiero R, Amaral S. Post-transplant lymphoproliferative disease after pediatric kidney transplant[J]. Front Pediatr, 2022, 10：1087864.
|
| 21 |
Womack J, Jimenez M. Common questions aboutinfectious mononucleosis[J]. Am Fam Physician, 2015, 91(6)：372-376.
|
| 22 |
You J, Kim M, Lee J, et al. Epstein-barr virus infection in children with renal transplantation： a single-centre experience[J]. Nephrology(Carlton), 2018, 23(11)：1039-1045.
|
| 23 |
Kazi S, Mathur A, Wilkie G, et al. Long-term follow up after thirdparty viral-specific cytotoxic lymphocytes for immunosuppression- and epstein-barr virus-associated lymphoproliferative disease[J].Haematologica, 2019, 104(8)：e356-e359.
|
| 24 |
Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression[J].Transplantation, 1999, 67(2)：299-303.
|
| 25 |
Al Hamed R, Bazarbachi AH, Mohty M. Epstein-barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation： a comprehensive review from pathogenesis to forthcoming treatment modalities[J]. Bone Marrow Transplant, 2020, 55(1)：25-39.
|
| 26 |
Giraldi E, Provenzi M, Conter V, et al. Risk-adapted treatment for severe B-lineage posttransplant lymphoproliferative disease after solid organ transplantation in children[J]. Transplantation, 2016, 100(2)：437-445.
|
| 27 |
González-Barca E, Domingo-Domenech E, Capote FJ, et al.Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J].Haematologica, 2007, 92(11)：1489-1494.
|
| 28 |
Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective,multicenter phase II trial[J]. J Clin Oncol, 2017, 35(5)：536-543.
|